Navigation Links
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Date:3/12/2009

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2008. Revenues for the year ended December 31, 2008 were $111,000 compared to $743,000 for the year ended December 31, 2007. Revenues for the fourth quarter of 2008 were $28,000, compared to $28,000 for the same period in 2007.

The net loss for the year ended December 31, 2008 was $71.6 million, or $0.79 per share, compared to $99.3 million, or $1.20 per share for the year ended December 31, 2007. Net loss in the fourth quarter of 2008 was $8.8 million or $0.09 per share, compared to a net loss of $27.0 million, or $0.32 per share, for the same period in 2007. Dendreon's total operating expenses for the year ended December 31, 2008 were $70.6 million compared to $102.4 million in 2007.

As of December 31, 2008, Dendreon had approximately $108.5 million in cash, cash equivalents, and short-term and long-term investments compared to $120.6 million as of December 31, 2007.

Recent Highlights:

  • Completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT clinical trial designed to assess the safety and efficacy of the investigational active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with androgen-independent prostate cancer. While Dendreon remains blinded to the data, the independent data monitoring committee (IDMC) reported to Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% Confidence Interval [0.610-1.051]). The IDMC observed no safety concerns and recommended that the study continue to its final analysis, which is expected to be completed by the end of April 2009
  • Filed an Invest
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Company Provides R&D Pipeline Update -, IRVINE, Calif., March ... financial results for the year ended,December 31, 2007. ISTA reported ... 2007, a 78% increase over the full-year 2006 results of,$33.0 ... 56% over,the fourth quarter of 2006., "2007 was a ...
... WEST CHESTER, Pa., March 6 VWR Funding, Inc., the,parent company of VWR International, LLC, ... its fourth quarter and year-end financial results., Who: ... Jack L. Wyszomierski, Executive ... Financial Officer, When: ...
... Chemistry Testing Market, FULLERTON, Calif., March ... ) announced today that it has launched ... an integrated work cell which,consolidates chemistry and ... addition to the company,s work cell family,combines ...
Cached Biology Technology:ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call 2Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell 2
(Date:8/28/2014)... million kilometres of new roads will be built worldwide ... Earth,s last wildernesses, where they bring an influx of ... an ambitious study has created a ,global roadmap, for ... balance the competing demands of development and environmental protection. ... that estimates that natural importance of ecosystems and a ...
(Date:8/28/2014)... to alert the world to Global Warming, has called ... stored underground. He says that Carbon Capture, combined with ... to avoid global warming getting out of control over ... York) made the call during his presentation to the ... are meeting to discuss Carbon Capture and Storage. ...
(Date:8/28/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned a ... of predatory arthropods. These animals lived in shallow ... related forms found in Jurassic strata. , ... shallow marine habitat and were fossilized some 435 ... denizens of the Silurian seas although they ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2
... nanotechnology fanciers suggest that, like proverbial birds of ... or clump together. This tendency, they ... manufacturing increases and the number of nanotechnology-enabled products ... Maynard, chief science advisor to the Project on ...
... completing the first large-scale report sequencing breast and colon ... studied the vast majority of protein-coding genes which now ... mutated in relatively few cancers. Their report, published ... indicates that while little is known about these less-commonly ...
... a reality today, but how can we find out about ... a full record of the Earths climate for several hundred ... that can be taken to the lab for analysis. Incredibly, ... Antarctic regions, and a European Science Foundation programme has a ...
Cached Biology News:Nanoparticle exposures happen, says expert 2Genome update defines landscape of breast and colon cancers 2Genome update defines landscape of breast and colon cancers 3European lead in reading past climates from ice cores 2European lead in reading past climates from ice cores 3
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
... Blunt-Ended PCR Cloning Kit, 40 ... efficient cloning of all PCR products ... TA cloning approaches by offering consistently ... as 25-fold more positive clones.Amplicons generated ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Immunogen: Synthetic peptide derived from ... protein (chromosome 17 open reading frame 37 ... for the C35 protein. On Western blots ... kDa band. Reactivity: Human (positive control: ...
Biology Products: